<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269618</url>
  </required_header>
  <id_info>
    <org_study_id>N.160</org_study_id>
    <nct_id>NCT02269618</nct_id>
  </id_info>
  <brief_title>Telehealth Program in Chronic Patients</brief_title>
  <official_title>Innovative Multidisciplinary Telehealth Program in COPD and CHF Patients: a Randomized Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Salvatore Maugeri</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized control study is to determine the feasibility and efficacy of an
      innovative multidisciplinary telehealth program in chronic obstructive pulmonary disease
      (COPD) and chronic heart failure (CHF) patients. 120 patients (1:1) will be included in the
      study and followed for 4 months and for additional 2 months of follow-up. The primary outcome
      is to improve tolerance capacity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD and CHF frequently coexist, causing a significant worsening in the quality of life of
      the patients and increasing morbidity and mortality. The prevalence of COPD in the CHF
      patients ranges from 20% to 32% of cases, and CHF is prevalent in more than 20% of patients
      with COPD.

      COPD and CHF patients are complicated and frail with a high risk of re-hospitalizations; for
      this reason an individualized and multidisciplinary program need to be implemented in these
      patients. The chronic disease trend is fluctuating, burdened by many exacerbations through a
      vicious circle with dyspnoea, decreased activity, new exacerbations, depression and social
      isolation, leading to death.

      The weight of evidence from a meta-analysis of randomized trials indicates that a
      multidisciplinary disease-management approach has the best outcomes in terms of prolonged
      survival and reduced hospital-readmission rates. Home-based management might, arguably, be
      the preferred approach after hospitalization of chronic diseases patients.

      Home-base management might provide an opportunity to prevent clinical deterioration and
      hospitalizations by a comprehensive, long-term intervention with regular reinforcement of
      patient adherence, knowledge, and skills. A personalized hospital-discharge programme seems
      to be the best approach to plan the follow-up care of patients with chronic diseases.

      These programmes, particularly important in the care of patients with multiple comorbidities,
      should include a routine self-management support, consisting in education to recognize
      symptoms early, to manage medical devices, to identify barriers to adherence to therapy such
      as adverse effects of drugs, and to check that the intensity of physical therapy is
      appropriate.

      Our study want to investigate feasibility and efficacy of a multidisciplinary telehealth and
      tele-rehabilitation home based program in patients with COPD and CHF. This is an integrated,
      multidisciplinary nurse and therapist oriented program; these two figures have a central role
      during home based intervention and became an essential interface in the dialogue between
      patient and specialist. The nurse and therapist, each for their competence, collect
      information, carry out education and training, verify adherence to drug and physical therapy,
      verify the quality of caregiver assistance. When needed, they require intervention of
      specialist for consultation or second-opinion.

      After drug therapy optimization and physical rehabilitation program definition, the patient
      will be allocated randomly into 2 groups: 1. Group A (usual care): the patients will be
      followed in the usual care manner by General Practitioner (GP) and routine specialist visits.
      2. Group B (Home-based intervention): the patients will be monitored at home for 4 months by
      nurse and therapist and they will perform an individual rehabilitative program including at
      least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with
      pedometer.

      At baseline, after 4 months and further 2 months of follow-up all patients in both groups
      will undergo to follows clinical and physical evaluations:

        1. ECG (T0; T4 if needed)

        2. Echocardiogram (T0, T4 if needed

        3. Spirometry (T0 or a spirometry available in the previous year)

        4. Arterial blood gases (T0; T4)

        5. Walking test (T0; T4; T6)

        6. Metabolic Holter monitoring using the Body Monitoring Multi-Sensor Armband (BMSA)
           (SenseWear) worn at the triceps of the right arm for at least 72 h. (T0; T4; T6)

      The questionnaires and scale :

        1. Minnesota (T0;T4;T6)

        2. COPD Assessment Test (CAT) (T0;T4;T6)

        3. Barthel (T0;T4;T6)

        4. Dyspnoea and muscle fatigue by Borg scale evaluation, referred by patient during his
           regular day (T0;T4;T6)

        5. Medical Research Council (MRC) scale for dyspnoea during regular day (T0;T4;T6)

        6. Physical activity scale for the elderly (PASE) (T0;T4;T6)

        7. Customer satisfaction (T4, only group B)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement tolerance capacity</measure>
    <time_frame>4 months and 6 months</time_frame>
    <description>The improvement in tolerance capacity will be measured by walking test performance (meters walked)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of hospitalisations for cardiovascular disease and /or respiratory disease</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of hospitalisations for all-cases</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy expenditure and duration and quantification of physical activity Energy expenditure and duration and quantification of physical activity</measure>
    <time_frame>4 months and 6 months</time_frame>
    <description>The outcome will be measured in a subgroup of patients using metabolic holter monitoring using the Body Monitoring Multi-Sensor Armband (BMSA) (SenseWear) worn at the triceps of the right arm for at least 72 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life</measure>
    <time_frame>4 months</time_frame>
    <description>The improvement in quality of life, measured by Minnesota Questionnaire and CAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of clinical instabilities without hospital admission</measure>
    <time_frame>4 months</time_frame>
    <description>The reduction of clinical instabilities will be measured by number of times that patients need to use antibiotics and/or corticosteroids and/or number of times that patients need to increase dosage of diuretic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of impairment/disability</measure>
    <time_frame>4 months</time_frame>
    <description>The reduction of impairment/disability will be measured with Barthel index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to at least 70% proposal rehabilitative sessions</measure>
    <time_frame>4 months and 6 months</time_frame>
    <description>The adherence will be calculated only in the group B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control group (Group A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group (Group B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:
Home-based telehealth program
Home-based rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home-based telehealth program</intervention_name>
    <description>Home-based telehealth program
Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.
Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms
Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor
Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need
Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises.</description>
    <arm_group_label>Intervention group (Group B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home-based rehabilitation</intervention_name>
    <description>Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer
Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)
Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient.</description>
    <arm_group_label>Intervention group (Group B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Usual care All patients will be followed also in usual care manner by their GPs.</description>
    <arm_group_label>Control group (Group A)</arm_group_label>
    <arm_group_label>Intervention group (Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD new GOLD classification (B, C and D class) and a spirometry in the previous year
             and

          -  Systolic and/or diastolic CHF defined at least by an echocardiogram performed in
             clinical stability; II, III and IV New York Heart Association class and optimized drug
             therapy.

          -  Informed consent signed

        Exclusion Criteria:

          -  Physical activity limitations caused by non-cardiac and/or pulmonary problems

          -  Obstructive Cardiomyopathies and/or myocarditis

          -  Non cardiac and/or pulmonary pathologies that would cause the death of the patient
             during the study

          -  Poor adherence and compliance of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Vitacca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione Salvatore Maugeri</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FSM Respiratory Unit</name>
      <address>
        <city>Lumezzane</city>
        <state>BS</state>
        <zip>25066</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri, Cardiology Unit</name>
      <address>
        <city>Lumezzane</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri, Telemedicine Service</name>
      <address>
        <city>Lumezzane</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009 Feb;11(2):130-9. doi: 10.1093/eurjhf/hfn013. Review.</citation>
    <PMID>19168510</PMID>
  </reference>
  <reference>
    <citation>Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, Cohn JN, Tognoni G, Latini R; Valsartan Heart Failure Trial Investigators. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007 Dec;13(10):797-804.</citation>
    <PMID>18068611</PMID>
  </reference>
  <reference>
    <citation>Macchia A, Monte S, Romero M, D'Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail. 2007 Sep;9(9):942-8. Epub 2007 Jul 12.</citation>
    <PMID>17627878</PMID>
  </reference>
  <reference>
    <citation>Almagro P, Castro A. Helping COPD patients change health behavior in order to improve their quality of life. Int J Chron Obstruct Pulmon Dis. 2013;8:335-45. doi: 10.2147/COPD.S34211. Epub 2013 Jul 24. Review.</citation>
    <PMID>23901267</PMID>
  </reference>
  <reference>
    <citation>Walters JA, Cameron-Tucker H, Courtney-Pratt H, Nelson M, Robinson A, Scott J, Turner P, Walters EH, Wood-Baker R. Supporting health behaviour change in chronic obstructive pulmonary disease with telephone health-mentoring: insights from a qualitative study. BMC Fam Pract. 2012 Jun 13;13:55. doi: 10.1186/1471-2296-13-55.</citation>
    <PMID>22694996</PMID>
  </reference>
  <reference>
    <citation>Vitacca M, Bianchi L, Guerra A, Fracchia C, Spanevello A, Balbi B, Scalvini S. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J. 2009 Feb;33(2):411-8. doi: 10.1183/09031936.00005608. Epub 2008 Sep 17.</citation>
    <PMID>18799512</PMID>
  </reference>
  <reference>
    <citation>Giordano A, Scalvini S, Zanelli E, Corr√† U, Longobardi GL, Ricci VA, Baiardi P, Glisenti F. Multicenter randomised trial on home-based telemanagement to prevent hospital readmission of patients with chronic heart failure. Int J Cardiol. 2009 Jan 9;131(2):192-9. doi: 10.1016/j.ijcard.2007.10.027. Epub 2008 Jan 28.</citation>
    <PMID>18222552</PMID>
  </reference>
  <reference>
    <citation>Paneroni M, Colombo F, Papalia A, Colitta A, Borghi G, Saleri M, Cabiaglia A, Azzalini E, Vitacca M. Is Telerehabilitation a Safe and Viable Option for Patients with COPD? A Feasibility Study. COPD. 2015 Apr;12(2):217-25. doi: 10.3109/15412555.2014.933794. Epub 2014 Aug 5.</citation>
    <PMID>25093419</PMID>
  </reference>
  <reference>
    <citation>McLean S, Nurmatov U, Liu JL, Pagliari C, Car J, Sheikh A. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD007718. doi: 10.1002/14651858.CD007718.pub2. Review.</citation>
    <PMID>21735417</PMID>
  </reference>
  <reference>
    <citation>Shaw RJ, McDuffie JR, Hendrix CC, Edie A, Lindsey-Davis L, Williams JW Jr. Effects of Nurse-Managed Protocols in the Outpatient Management of Adults with Chronic Conditions [Internet]. Washington (DC): Department of Veterans Affairs; 2013 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK241377/</citation>
    <PMID>25210722</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Salvatore Maugeri</investigator_affiliation>
    <investigator_full_name>Michele Vitacca</investigator_full_name>
    <investigator_title>Responsible of Respiratory Unit</investigator_title>
  </responsible_party>
  <keyword>Telehealth, Home-based, rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

